

TICKBORNE DISEASES OF THE UNITED STATES

*A Reference Manual
for Health Care Providers*

Second Edition, 2014



**U.S. Department of
Health and Human Services**
Centers for Disease
Control and Prevention

Tick ID



BLACKLEGGED TICK
Ixodes scapularis

Where found: Widely distributed in the northeastern and upper midwestern United States.

Transmits: Lyme disease, anaplasmosis, babesiosis, and Powassan disease.

Comments: The greatest risk of being bitten exists in the spring, summer and fall. However, adults may be out searching for a host any time winter temperatures are above freezing. Stages most likely to bite humans are nymphs and adult females.



LONE STAR TICK
Amblyomma americanum

Where found: Widely distributed in the southeastern and eastern United States.

Transmits: *Ehrlichia chaffeensis* and *Ehrlichia ewingii* (which cause human ehrlichiosis), tularemia, and STARI.

Comments: A very aggressive tick that bites humans. The adult female is distinguished by a white dot or "lone star" on her back. Lone star tick saliva can be irritating; redness and discomfort at a bite site does not necessarily indicate an infection. The nymph and adult females most frequently bite humans and transmit disease.



AMERICAN DOG TICK
Dermacentor variabilis

Where found: Widely distributed east of the Rocky Mountains. Also occurs in limited areas on the Pacific Coast.

Transmits: Tularemia and Rocky Mountain spotted fever.

Comments: The highest risk of being bitten occurs during spring and summer. Dog ticks are sometimes called wood ticks. Adult females are most likely to bite humans.



Engorged female *Ixodes scapularis* tick. Color may vary.



NOTE: Illustrations are not to scale.

Tick ID



BROWN DOG TICK

Rhipicephalus sanguineus

Where found: Worldwide.

Transmits: Rocky Mountain spotted fever (in the southwestern U.S. and along the U.S.-Mexico border).

Comments: Dogs are the primary host for the brown dog tick in each of its life stages, but the tick may also bite humans or other mammals.



Steve Jacobs, PSU Entomology

GROUNDHOG TICK

Ixodes cookei

Where found: Throughout the eastern half of the U.S. and Canada.

Transmits: Powassan disease.

Comments: Also called woodchuck ticks. All life stages feed on a variety of warm-blooded animals, including groundhogs, skunks, squirrels, raccoons, foxes, weasels, and occasionally people and domestic animals.



GULF COAST TICK

Amblyomma maculatum

Where found: Coastal areas of the U.S. along the Atlantic coast and the Gulf of Mexico.

Transmits: *Rickettsia parkeri* rickettsiosis, a form of spotted fever.

Comments: Larvae and nymphs feed on birds and small rodents, while adult ticks feed on deer and other wildlife. Adult ticks have been associated with transmission of *R. parkeri* to humans.

4



ROCKY MOUNTAIN WOOD TICK

Dermacentor andersoni

Where found: Rocky Mountain states and southwestern Canada from elevations of 4,000 to 10,500 feet.

Transmits: Rocky Mountain spotted fever, Colorado tick fever, and tularemia.

Comments: Adult ticks feed primarily on large mammals. Larvae and nymphs feed on small rodents. Adult ticks are primarily associated with pathogen transmission to humans.



O. hermsi tick, before and after feeding. Photo taken by Gary Hettrick RML, NIAID.

SOFT TICK

Ornithodoros spp.

Where found: Throughout the western half of the U.S. and southwestern Canada.

Transmits: Tick-borne relapsing fever (*Borrelia hermsii*, *B. parkerii*, or *B. turicatae*)

Comments: Humans typically come into contact with soft ticks when they sleep in rodent infested cabins. The ticks emerge at night and feed briefly while the person is sleeping. The bites are painless, and most people are unaware that they have been bitten.



WESTERN BLACKLEGGED TICK

Ixodes pacificus

Where found: Along the Pacific coast of the U.S., particularly northern California.



Transmits: Anaplasmosis and Lyme disease.

Comments: Nymphs often feed on lizards, as well as other small animals. As a result, rates of infection are usually low (~1%) in the adult, the stage most likely to bite humans.



5

Overview of Tickborne Diseases

Selected Tickborne Diseases Reported to CDC, U.S., 2012



6



NOTE: Each dot represents one case. Cases are reported from the infected person's county of **residence**, not necessarily the place where they were infected.

NOTE: During 2012, babesiosis was reportable in Alabama, California, Connecticut, Delaware, Indiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Hampshire, New Jersey, New York, North Dakota, Oregon, Rhode Island, Tennessee, Vermont, Washington, Wisconsin, and Wyoming. CDC was not notified through the national surveillance system of cases in other states.

NOTE: In 2012, no cases of tickborne illness were reported from Hawaii. In 2012, Alaska reported ten travel-related cases of Lyme disease.


7

Anaplasmosis

AGENT

Anaplasma phagocytophilum

SIGNS/SYMPTOMS



WHERE FOUND

Anaplasmosis is most frequently reported from the upper midwest and northeastern U.S. in areas that correspond with the known geographic distribution of Lyme disease.

Anaplasmosis and ehrlichiosis have similar clinical presentations, but they are transmitted by two different species of ticks and generally occur in different regions of the U.S.

Anaplasmosis was formerly known as Human Granulocytic Ehrlichiosis (HGE).

INCUBATION PERIOD: 1–2 weeks

SIGNS AND SYMPTOMS

- Fever, chills
- Severe headache
- Malaise
- Myalgia
- Gastrointestinal symptoms (nausea, vomiting, diarrhea, anorexia)
- Cough
- Rash (rare cases)
- Stiff neck*
- Confusion*

* May present later (5 days after onset of symptoms) and may be prevented by early treatment.

The list at left presents symptoms commonly seen with anaplasmosis. However, it is important to note that few people will develop all symptoms and the number and combination of symptoms varies greatly from person to person.



Confirmation of the diagnosis is based on laboratory testing, but antibiotic therapy should not be delayed in a patient with a suggestive clinical presentation.

GENERAL LABORATORY FINDINGS

Typically Observed During the First Week of Clinical Disease:

- Mild anemia
- Thrombocytopenia
- Leukopenia (characterized by relative and absolute lymphopenia and a left shift)
- Mild to moderate elevations in hepatic transaminases may occur in some patients.
- Visualization of morulae in the cytoplasm of granulocytes during examination of blood smears is highly suggestive of a diagnosis; however, blood smear examination is insensitive and should never be relied upon solely to rule anaplasmosis in or out.

LABORATORY CONFIRMATION

Antibodies to *A. phagocytophilum* are detectable 7–10 days after illness onset. The gold-standard serologic test looks for a four-fold change in antibody titers using immunofluorescence assay (IFA) on paired samples. The first sample should be taken within the first week of illness and the second should be taken 2 to 4 weeks later.

- Demonstration of a four-fold change in IgG-specific antibody titer by immunofluorescence assay (IFA) test in paired serum samples; or
- Detection of DNA by PCR of whole blood. This method is most sensitive within the first week of illness; sensitivity may decrease after administration of antibiotics.

NOTE: IgM antibodies are less specific than IgG antibodies and are more likely to generate false positives. IgM results alone should not be used for laboratory diagnosis.

NOTE: Consider the possibility of coinfection with *Babesia microti* and/or *Borrelia burgdorferi*.

NOTE: Antibody titers are frequently negative in the first 7–10 days of illness, thus serologic tests may be falsely negative during this time period.

LABS

Anaplasmosis

AGENT
Anaplasma phagocytophilum

TREATMENT

Anaplasmosis, ehrlichiosis and Rocky Mountain spotted fever are treated in the same manner with doxycycline. Clinical suspicion of any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and even death. The regimens listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health conditions, pregnancy status, or allergies. Consult an infectious disease specialist in cases of documented pregnancy or life-threatening allergies to doxycycline.

| AGE CATEGORY | DRUG | DOSAGE | MAXIMUM | DURATION (DAYS) |
|---------------------------------------|-------------|--|-------------|--|
| Adults | Doxycycline | 100 mg twice per day, orally or IV | 100 mg/dose | Patients with suspected anaplasmosis infection should be treated with doxycycline for 10-14 days to provide appropriate length of therapy for possible incubating co-infection with Lyme disease |
| Children weighing <100 lbs. (45.4 kg) | Doxycycline | 2.2 mg/kg per dose twice per day, orally or IV | 100 mg/dose | |



NOTE: Use doxycycline as first-line treatment for suspected anaplasmosis in patients of all ages. The use of doxycycline to treat suspected anaplasmosis in children is recommended by both the CDC and the American Academy of Pediatrics Committee on Infectious Diseases. Use of antibiotics other than doxycycline increases the risk of patient death. At the recommended dose and duration needed to treat anaplasmosis, no evidence has been shown to cause staining of permanent teeth, even when five courses are given before the age of eight.

10

REFERENCES

Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. *Clin Infect Dis* 2001; 32: 862–870.

Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis—U.S.: a practical guide for physicians and other health-care and public health professionals. *MMWR* 2006; 55 (No.RR-4).

Engel J, Bradley K, et al. Revision of the national surveillance case definition for ehrlichiosis (ehrlichiosis/anaplasmosis). Council of State and Territorial Epidemiologists, Infectious Diseases Committee, 2007 Position Statement. <http://cymcdn.com/sites/www.cste.org/resource/resmgr/PS/07-ID-03.pdf>

Gelfand JA, Vannier E. *Ehrlichia chaffeensis* (human monocytotropic ehrlichiosis), *Anaplasma phagocytophilum* (human granulocytotropic anaplasmosis) and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases*. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005. p. 2310–2318.

Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006; 43: 1089–1134.

11

Babesiosis

AGENT

Babesia microti
and other *Babesia* species

SIGNS/SYMPTOMS



WHERE FOUND

Babesiosis is most frequently reported from the northeastern and upper midwestern United States in areas where *Babesia microti* is endemic. Sporadic cases of infection caused by novel *Babesia* agents have been detected in other U.S. regions, including the West Coast. In addition, transfusion-associated cases of babesiosis can occur anywhere in the country.

INCUBATION PERIOD: 1–9+ weeks

SIGNS AND SYMPTOMS

- Fever, chills, sweats
- Malaise, fatigue
- Myalgia, arthralgia, headache
- Gastrointestinal symptoms, such as anorexia and nausea (less common: abdominal pain, vomiting)
- Dark urine
- Less common: cough, sore throat, emotional lability, depression, photophobia, conjunctival injection
- Mild splenomegaly, mild hepatomegaly, or jaundice may occur in some patients

NOTE: Not all infected persons are symptomatic or febrile. The clinical manifestations, if any, usually develop within several weeks after the exposure but may develop or recur months later (for example, in the context of surgical splenectomy).

Babesiosis is caused by parasites that infect red blood cells. Most U.S. cases are caused by *Babesia microti*, which is transmitted by *Ixodes scapularis* ticks, primarily in the Northeast and upper Midwest. *Babesia* parasites also can be transmitted via transfusion, anywhere, at any time of the year. To date, no *Babesia* tests have been licensed for screening blood donors. Congenital transmission also has been reported.

Babesia infection can range from asymptomatic to life threatening. Risk factors for severe babesiosis include asplenia, advanced age, and impaired immune function. Severe cases can be associated with marked thrombocytopenia, disseminated intravascular coagulation, hemodynamic instability, acute respiratory distress, renal failure, hepatic compromise, altered mental status, and death.

12

GENERAL LABORATORY FINDINGS

- Decreased hematocrit due to hemolytic anemia
- Thrombocytopenia
- Elevated serum creatinine and blood urea nitrogen (BUN) values
- Mildly elevated hepatic transaminase values

LABORATORY DIAGNOSIS

- Identification of intraerythrocytic *Babesia* parasites by light-microscopic examination of a peripheral blood smear; or
- Positive *Babesia* (or *B. microti*) polymerase chain reaction (PCR) analysis; or
- Isolation of *Babesia* parasites from a whole blood specimen by animal inoculation (in a reference laboratory).

SUPPORTIVE LABORATORY CRITERIA

- Demonstration of a *Babesia*-specific antibody titer by indirect fluorescent antibody (IFA) testing for total immunoglobulin (Ig) or IgG.

NOTE: If the diagnosis of babesiosis is being considered, manual (nonautomated) review of blood smears should be requested explicitly. In symptomatic patients with acute infection, *Babesia* parasites typically can be detected by blood-smear examination, although multiple smears may need to be examined. Sometimes it can be difficult to distinguish between *Babesia* and malaria parasites and even between parasites and artifacts (such as stain or platelet debris). Consider having a reference laboratory confirm the diagnosis and the species. In some settings, molecular techniques can be useful for detecting and differentiating among *Babesia* species.

NOTE: Antibody detection by serologic testing can provide supportive evidence for the diagnosis but does not reliably distinguish between active and prior infection.

13

LABS

Babesiosis

Ehrlichiosis

Lyme
Disease

Rocky
Mountain
Spotted Fever

Tularemia

Other
Tickborne
Diseases

Tick Bites/
Prevention

TREATMENT

Treatment decisions and regimens should consider the patient’s age, clinical status, immunocompetence, splenic function, comorbidities, pregnancy status, other medications, and allergies. Expert consultation is recommended for persons who have or are at risk for severe or relapsing infection or who are at either extreme of age.

For ill patients, babesiosis usually is treated for at least 7–10 days with a combination of two medications—typically, either atovaquone PLUS azithromycin; OR clindamycin PLUS quinine (this combination is the standard of care for severely ill patients). The typical regimens for adults are provided in the table below.

| AGE CATEGORY | | DRUG | DOSAGE | MAXIMUM | DURATION (DAYS) |
|--------------|--------------------|---------------|--|-----------------|-----------------|
| Adults | Prescribe together | Atovaquone | 750 mg orally every 12 hours | N/A | 7–10 |
| | | Azithromycin | On the first day, give a total dose in the range of 500–1000 mg orally; on subsequent days, give a total daily dose in the range of 250–1000 mg* | 1000 mg per day | 7–10 |
| | OR | | | | |
| | Prescribe together | Clindamycin** | 300–600 mg IV every 6 hours OR 600 mg orally every 8 hours** | N/A | 7–10 |
| | | Quinine** | 650 mg orally every 6–8 hours | N/A | 7–10 |

* The upper end of the range (600–1000 mg per day) has been used for adults who are immunocompromised.

** The standard of care for patients with severe babesiosis (e.g., with parasitemia levels ≥10% and/or organ-system dysfunction) is quinine plus clindamycin; typically, the clindamycin is administered intravenously. Such patients also might require or benefit from exchange transfusions, vasopressor therapy, mechanical ventilation, or dialysis.

NOTE: Most persons without clinical manifestations of infection do not require treatment. However, consider treating persons who have had demonstrable parasitemia for more than 3 months.

REFERENCES

Centers for Disease Control and Prevention. Babesiosis surveillance—18 states, 2011. *MMWR* 2012;61:505–9.


Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-associated babesiosis in the United States: a description of cases. *Ann Intern Med* 2011;115:509–19.

Vannier E, Krause PJ. Human babesiosis. *N Engl J Med* 2012;366:2397–407.

Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2006;43:1089–134. Erratum in: *Clin Infect Dis* 2007;45:941.

Wormser GP, Prasad A, Neuhaus E, et al. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with *Babesia microti* infection. *Clin Infect Dis* 2010;50:381–6.

REFERENCES



WHERE FOUND

Ehrlichiosis is most frequently reported from the southeastern and south-central U.S., from the eastern seaboard extending westward to Texas. The areas from which cases are reported correspond with the known geographic distribution of the lone star tick (*Amblyomma americanum*), which is associated with transmission of both *E. chaffeensis* and *E. ewingii*. Three states (Oklahoma, Missouri, Arkansas) account for 35% of all reported *E. chaffeensis* infections.

INCUBATION PERIOD: 1–2 weeks

SIGNS AND SYMPTOMS

- Fever
- Headache
- Chills
- Malaise
- Muscle pain
- Gastrointestinal symptoms (nausea, vomiting, diarrhea, anorexia)
- Confusion
- Conjunctival injection
- Rash (in up to 60% of children, less than 30% of adults)

Ehrlichiosis and anaplasmosis have a similar clinical presentation, but they are transmitted by two different species of ticks and generally occur in different regions of the U.S.

The above list presents symptoms commonly seen with ehrlichiosis. However, it is important to note that few people will develop all symptoms and the number and combination of symptoms varies greatly from person to person.



Confirmation of the diagnosis is based on laboratory testing, but antibiotic therapy should not be delayed in a patient with a suggestive clinical presentation.

GENERAL LABORATORY FINDINGS

Typically Observed During the First Week of Clinical Disease:

- Mild anemia
- Thrombocytopenia
- Leukopenia (characterized by relative and absolute lymphopenia and a left shift)
- Mild to moderate elevations in hepatic transaminases may occur in some patients
- During the acute stage of illness, morulae may be detected in about 20% of patients. *E. chaffeensis* most commonly infects monocytes, whereas *E. ewingii* more commonly infects granulocytes.

LABORATORY CONFIRMATION

Antibodies to *Ehrlichia* are detectable 7–10 days after illness onset. The gold-standard serologic test looks for a four-fold change in IgG-specific antibody titers using immunofluorescence assay (IFA) on paired samples. The first sample should be taken within the first week of illness and the second should be taken 2 to 4 weeks later.

- Demonstration of a four-fold change in IgG-specific antibody titer by immunofluorescence assay (IFA) test in paired serum samples; or
- Detection of DNA by PCR on whole blood. This method is most sensitive within the first week of illness; may decrease in sensitivity after administration of antibiotics.

NOTE: IgM antibodies are less specific than IgG antibodies and are more likely to generate false positive results. IgM results alone should not be used for laboratory diagnosis.

NOTE: Antibody titers are frequently negative in the first 7–10 days of illness, thus serologic tests may be falsely negative during this time period.

Anaplasmosis, ehrlichiosis and Rocky Mountain spotted fever are treated in the same manner with doxycycline. Clinical suspicion of any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and death. The regimens listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health conditions, pregnancy status, or allergies. Consult an infectious disease specialist in cases of documented pregnancy or life-threatening allergies to doxycycline.

| AGE CATEGORY | DRUG | DOSAGE | MAXIMUM | DURATION (DAYS) |
|---------------------------------------|-------------|--|-------------|---|
| Adults | Doxycycline | 100 mg twice per day, orally or IV | 100 mg/dose | Patients should be treated for at least 3 days after the fever subsides and until there is evidence of clinical improvement. Minimum course of treatment is 5–7 days. |
| Children weighing <100 lbs. (45.4 kg) | Doxycycline | 2.2 mg/kg per dose twice per day, orally or IV | 100 mg/dose | |



NOTE: Use doxycycline as first-line treatment for suspected ehrlichiosis in patients of all ages. The use of doxycycline to treat suspected ehrlichiosis in children is recommended by both the CDC and the American Academy of Pediatrics Committee on Infectious Diseases. Use of antibiotics other than doxycycline increases the risk of patient death. At the recommended dose and duration needed to treat ehrlichiosis, no evidence has been shown to cause staining of permanent teeth, even when five courses are given before the age of eight.

REFERENCES

Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis—U.S.: a practical guide for physicians and other health-care and public health professionals. *MMWR* 2006; 55 (No.RR-4).

Dumler JS, Madigan JE, Pusterla N, Bakken JS. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. *Clin Infect Dis* 2007 Jul 15;45 Suppl 1:S45–51.

Engel J, Bradley K, et al. Revision of the national surveillance case definition for ehrlichiosis. Council of State and Territorial Epidemiologists, Infectious Diseases Committee, 2007 Position Statement. <http://cymcdn.com/sites/www.cste.org/resource/resmgr/PS/07-ID-03.pdf>

Gelfand JA, Vannier E. *Ehrlichia chaffeensis* (human monocytotropic ehrlichiosis), *Anaplasma phagocytophilum* (human granulocytotropic anaplasmosis) and other ehrlichiae. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005. p. 2310–2318.



INCUBATION PERIOD: 3–30 days

SIGNS AND SYMPTOMS

Localized Stage[†]

- Erythema migrans (EM)—red ring-like or homogenous expanding rash; classic rash not present in all cases. See examples on following pages.
- Flu-like symptoms – malaise, headache, fever, myalgia, arthralgia
- Lymphadenopathy

Disseminated Stage

- Multiple secondary annular rashes
- Flu-like symptoms
- Lymphadenopathy

Rheumatologic Manifestations

- Transient, migratory arthritis and effusion in one or multiple joints
- Migratory pain in tendons, bursae, muscle, and bones
- Baker's cyst
- If untreated, arthritis may recur in same or different joints

Cardiac Manifestations

- Conduction abnormalities, e.g. atrio-ventricular node block
- Myocarditis, pericarditis

Neurologic Manifestations

- Bell's palsy or other cranial neuropathy
- Meningitis
- Motor and sensory radiculoneuropathy, mononeuritis multiplex
- Subtle cognitive difficulties
- Encephalitis, encephalomyelitis, subtle encephalopathy, pseudotumor cerebri (all rare)

Additional Manifestations

- Conjunctivitis, keratitis, uveitis
- Mild hepatitis
- Splenomegaly

[†]During the **localized** (early) stage of illness, Lyme disease may be diagnosed clinically in patients who present with an EM rash. Serologic tests may be insensitive at this stage. During **disseminated** disease, however, serologic tests are usually positive.

GENERAL LABORATORY FINDINGS

- Elevated erythrocyte sedimentation rate
- Mildly elevated hepatic transaminases
- Microscopic hematuria or proteinuria
- In Lyme meningitis, CSF typically shows lymphocytic pleocytosis, slightly elevated protein, and normal glucose.

LABORATORY DIAGNOSIS

- Demonstration of diagnostic IgM or IgG antibodies in serum. A two-tier testing protocol is recommended—EIA or IFA should be performed first; if positive or equivocal it is followed by a Western blot.
- Isolation of organism from a clinical specimen.
- In suspected Lyme meningitis, testing for intrathecal IgM or IgG antibodies may be helpful.

NOTES ON SEROLOGIC TESTS FOR LYME DISEASE

- Serologic tests are insensitive during the first few weeks of infection. During this stage, patients with an EM rash may be diagnosed clinically. While not necessary, acute and convalescent titers may be helpful in some cases.
- In persons with illness > 1 month, only IgG testing should be performed (not IgM). A positive IgM test alone is not sufficient to diagnose current disease.
- Due to antibody persistence, single positive serologic test results cannot distinguish between active and past infection.
- Serologic tests cannot be used to measure treatment response.
- Enzyme immunoassay (EIA) and immunofluorescence assay (IFA) tests have low specificity and may yield false-positive results. They may cross-react with antibodies to commensal or pathogenic spirochetes, some viral infections (e.g., varicella, Epstein-Barr virus), or certain autoimmune diseases (e.g., lupus).

LYME DISEASE OR STARI?

An erythema migrans-like rash has also been described in humans following bites of the lone star tick, *Amblyomma americanum*. This condition has been named Southern Tick-Associated Rash Illness (STARI). Although the rash may be accompanied by flu-like symptoms, long-term sequelae have not been reported. Because the cause of STARI is unknown, diagnostic blood tests are not available.

Lone star ticks can be found from central Texas and Oklahoma eastward across the southern states and along the Atlantic coast as far north as Maine.

It is not known whether antibiotic treatment is necessary or beneficial for patients with STARI. Nevertheless, because STARI resembles early Lyme disease, physicians often treat patients with the same antibiotics recommended for Lyme disease.

NOTE: Coinfection with *B. microti* and/or *A. phagocytophilum* should be considered in patients who present with initial symptoms that are more severe than are commonly observed with Lyme disease alone, especially in those who have high-grade fever for more than 48 hours despite appropriate antibiotic therapy or who have unexplained leukopenia, thrombocytopenia, or anemia. Coinfection might also be considered in patients whose erythema migrans skin lesion has resolved but have persistent flu-like symptoms.

Treatment regimens listed in the following table are for localized (early) Lyme disease. Treatment guidelines for patients with disseminated (late) Lyme disease are outlined in the reference below.[†]

These regimens are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health conditions, pregnancy status or allergies. Consult an infectious disease specialist for the most current treatment guidelines or for individual patient treatment decisions.

| AGE CATEGORY | DRUG | DOSAGE | MAXIMUM | DURATION, DAYS (RANGE) |
|--------------|-------------------|---|-----------------|------------------------|
| Adults | Doxycycline | 100 mg, twice per day orally | N/A | 14 (14–21) |
| | Cefuroxime axetil | 500 mg, twice per day orally | N/A | 14 (14–21) |
| | Amoxicillin | 500 mg, three times per day orally | N/A | 14 (14–21) |
| Children | Amoxicillin | 50 mg/kg per day orally, divided into 3 doses | 500 mg per dose | 14 (14–21) |
| | Doxycycline | 4 mg/kg per day orally, divided into 2 doses | 100 mg per dose | 14 (14–21) |
| | Cefuroxime axetil | 30 mg/kg per day orally, divided into 2 doses | 500 mg per dose | 14 (14–21) |

NOTE: For patients intolerant of amoxicillin, doxycycline, and cefuroxime axetil, the macrolides azithromycin, clarithromycin, or erythromycin may be used, although they have a lower efficacy. Patients treated with macrolides should be closely observed to ensure resolution of clinical manifestations.

REFERENCES

Agüero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. Clin Microbiol Rev 2005;18(3):484-509.

American Academy of Pediatrics. Lyme disease (Lyme borreliosis, *Borrelia burgdorferi* infection). In: Pickering LK, Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012:474–479.

Centers for Disease Control and Prevention. Notice to readers: caution regarding testing for Lyme disease. MMWR 2005; 54:125–126.

Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR 1995;44:590–591.

Halperin JJ, Baker P, Wormser GP. Common misconceptions about Lyme disease. Am J Med 2013;126(3):264.

Marques A. Lyme Disease: A Review. Curr Allergy Asthma Resp 2010, 10: 13-20.

Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002;136:421–8.

Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012;379(9814):461-73.

Steere AC. *Borrelia burgdorferi* (Lyme Disease, Lyme borreliosis). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005:2798–2809.

[†]Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089–1134.

Lyme Disease

AGENT
Borrelia burgdorferi

The erythema migrans (EM) rash occurs in 70–80% of patients with Lyme disease. EM rashes expand slowly over a few days after which they may develop a “bull’s-eye” appearance consisting of a red ring with central clearing. However, EM may take alternate forms—solid lesions, blue-purple hues, and crusted or blistering lesions have all been documented. The rash is not painful or pruritic, but it may be warm to the touch. If early localized Lyme disease is not treated, patients may develop multiple secondary circular rashes as spirochetes disseminate throughout the body.

PHOTOS



Photo courtesy of Taryn Holman



Photo courtesy of Yevgeniy Balagula



Photo courtesy of Bernard Cohen

Classic EM—Circular red rash with central clearing that slowly expands

Bluish hue without central clearing

Red, expanding lesion with central crust

24

PHOTOS



Photo courtesy of Alison Young



Photo courtesy of Robin Stevenson



Photo courtesy of Bernard Cohen

Red, oval-shaped plaque on trunk

Red-blue lesion with central clearing on back of knee

Early disseminated Lyme disease—multiple red lesions with dusky centers



Tick bite with mild allergic reaction. **Not an erythema migrans.** Allergic reactions typically appear within the first 48 hours of tick attachment and are usually <5 cm in diameter.

Special thanks to DermAtlas for providing the photographs.

25

Lyme
Disease/
STARI

Rocky
Mountain
Spotted Fever

Tularemia

Other
Tickborne
Diseases

Tick Bites/
Prevention

Rocky Mountain Spotted Fever

AGENT
Rickettsia rickettsii

SIGNS/SYMPTOMS



WHERE FOUND

Although Rocky Mountain spotted fever cases have been reported throughout most of the contiguous U.S., five states (North Carolina, Oklahoma, Arkansas, Tennessee, and Missouri) account for over 60% of RMSF cases.

Rocky Mountain spotted fever has become increasingly common in certain areas of Arizona over the last several years. Between 2003 and 2012 over 250 cases and 19 fatalities occurred. RMSF can be rapidly fatal if not treated within the first 5 days of symptoms. Before tetracycline antibiotics were available, case fatality rates ranged from 20–80%.

INCUBATION PERIOD: 2–14 days

SIGNS AND SYMPTOMS

- Fever, chills
- Severe headache
- Malaise
- Myalgia
- Gastrointestinal symptoms (nausea, vomiting, anorexia, abdominal pain, diarrhea, abdominal tenderness)
- Cough
- Conjunctival injection, ± photophobia
- Altered mental status
- Focal neurologic deficits, including cranial or peripheral motor nerve paralysis or sudden transient deafness

Maculopapular Rash

- Typically appears 2–5 days after the onset of fever
- Small, flat, pink, non-itchy spots (macules) initially appear on the wrists, forearms, and ankles then spread to the trunk and sometimes palms and soles.
- Rash may not develop until late in the disease process, after treatment should have already begun. Approximately 10% of RMSF patients never develop a rash at all.

- Consider RMSF if other signs and symptoms support a diagnosis, even if a rash is not present.

Petechial Rash

- Red to purple spots (petechiae) are usually not seen until day 6 or later after onset of symptoms.
- Petechial rash is considered a sign of progression to severe disease. Every attempt should be made to begin treatment before petechiae develop.

26

NOTE: Neurologic symptoms are typically not seen until later in the disease progression and may be prevented with early treatment.



Confirmation of the diagnosis is based on laboratory testing, but antibiotic therapy should not be delayed in a patient with a suggestive clinical presentation. Antibiotics are less likely to prevent fatal outcome from RMSF if started after day 5 of symptoms.

GENERAL LABORATORY FINDINGS

- Thrombocytopenia
- Mildly elevated hepatic transaminase levels
- Hyponatremia

LABORATORY CONFIRMATION

Antibodies to *R. rickettsii* are detectable 7–10 days after illness onset. The gold-standard serologic test looks for a four-fold change in antibody titers using immunofluorescence assay (IFA) on paired samples. The first sample should be taken within the first week of illness and the second should be taken 2 to 4 weeks later.

- Demonstration of a four-fold change in IgG-specific antibody titer by immunofluorescence assay (IFA) test in paired serum samples; or
- Detection of DNA in a skin biopsy of rash by polymerase chain reaction (PCR) assay (generally unreliable for acute blood samples).
- Immunohistochemical (IHC) staining of organism

NOTE: IgM antibodies are less specific than IgG antibodies and are more likely to generate false positives. IgM results alone should not be used for laboratory diagnosis.

NOTE: Antibody titers are frequently negative in the first 7–10 days of illness, thus serologic tests may be falsely negative during this time period.

27

LABS

Rocky
Mountain
Spotted Fever

Tularemia

Other
Tickborne
Diseases

Tick Bites/
Prevention

Rocky Mountain Spotted Fever

AGENT
Rickettsia rickettsii

TREATMENT

Anaplasmosis, ehrlichiosis and Rocky Mountain spotted fever are treated in the same manner with doxycycline.[†] Clinical suspicion of any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and even death. The regimens listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health conditions, pregnancy status, or allergies. Consult an infectious disease specialist in cases of pregnancy or documented life-threatening allergies to doxycycline.

| AGE CATEGORY | DRUG | DOSAGE | MAXIMUM | DURATION (DAYS) |
|---------------------------------------|-------------|--|-------------|---|
| Adults | Doxycycline | 100 mg twice per day, orally or IV | 100 mg/dose | Patients should be treated for at least 3 days after the fever subsides and until there is evidence of clinical improvement. Minimum course of treatment is 5–7 days. |
| Children weighing <100 lbs. (45.4 kg) | Doxycycline | 2.2 mg/kg per dose twice per day, orally or IV | 100 mg/dose | |



NOTE: Use doxycycline as the first-line treatment for suspected RMSF in patients of all ages. The use of doxycycline to treat suspected RMSF in children is recommended by both the CDC and the American Academy of Pediatrics Committee on Infectious Diseases. Use of antibiotics other than doxycycline increases the risk of patient death. At the recommended dose and duration needed to treat RMSF, no evidence has been shown to cause staining of permanent teeth, even when five courses are given before the age of eight.

REFERENCES

[†]Centers for Disease Control and Prevention. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis—U.S.: A practical guide for physicians and other health-care and public health professionals. *MMWR* 2006; 55 (No.RR-4).

Smithee L, et al. Public health reporting and national notification for spotted fever rickettsiosis (including Rocky Mountain spotted fever). Council of State and Territorial Epidemiologists, Infectious Diseases Committee, 2009 Position Statement. <http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/09-ID-16.pdf>

Walker DH, Raoult D. *Rickettsia rickettsii* and other spotted fever group rickettsiae (Rocky Mountain spotted fever and other spotted fevers). In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005. p. 2287–2295.

REFERENCES



INCUBATION PERIOD:

3–5 days (range 1–21 days)

NOTE: The clinical presentation of tularemia will depend on a number of factors, including the portal of entry.

WHERE FOUND

In the U.S., naturally occurring tularemia infections have been reported from all states except Hawaii. Ticks that transmit tularemia to humans include the dog tick (*Dermacentor variabilis*), the wood tick (*Dermacentor andersoni*), and the lone star tick (*Amblyomma americanum*). Other transmission routes include inhalation and direct inoculation.

SIGNS AND SYMPTOMS

- Fever, chills
 - Headache
 - Malaise, fatigue
 - Anorexia
 - Myalgia
 - Chest discomfort, cough
 - Sore throat
 - Vomiting, diarrhea
 - Abdominal pain
- (Ulcers) Glandular
- Localized lymphadenopathy
 - Cutaneous ulcer at infection site (not always present)

- Oculoglandular
- Photophobia
 - Excessive lacrimation
 - Conjunctivitis
 - Preauricular, submandibular and cervical lymphadenopathy
- Oropharyngeal
- Severe throat pain
 - Cervical, preparotid, and/or retropharyngeal lymphadenopathy

- Pneumonic
- Non-productive cough
 - Substernal tightness
 - Pleuritic chest pain
 - Hilar adenopathy, infiltrate, or pleural effusion may be present on chest X-ray
- Typhoidal
- Characterized by any combination of the general symptoms (without localizing symptoms of other syndromes)

GENERAL LABORATORY FINDINGS

- Leukocyte count and sedimentation rate may be normal or elevated
- Thrombocytopenia
- Hyponatremia
- Elevated hepatic transaminases
- Elevated creatine phosphokinase
- Myoglobinuria
- Sterile pyuria

LABORATORY DIAGNOSIS

- Demonstration of a four-fold change in antibody titer in paired sera; or
- Isolation of organism from a clinical specimen; or
- Detection of organism by immunofluorescence assay (IFA) test or a single elevated serum antibody titer is supportive of the diagnosis; however, a single antibody titer should be confirmed by either one of the methods above.

The regimens listed below are guidelines only and may need to be adjusted depending on a patient’s age, medical history, underlying health conditions, pregnancy status or allergies. Consult an infectious disease specialist for the most current treatment guidelines or for individual patient treatment decisions.

| AGE CATEGORY | DRUG | DOSAGE | MAXIMUM | DURATION (DAYS) |
|--------------|----------------|--|---|-----------------|
| Adults | Streptomycin | 1 g IM twice daily | 2 g per day | Minimum 10 |
| | Gentamicin* | 5 mg/kg IM or IV daily (with desired peak serum levels of at least 5 mcg/mL) | Monitor serum drug levels | Minimum 10 |
| | Ciprofloxacin* | 400 mg IV or PO twice daily | N/A | 10–14 |
| | Doxycycline | 100 mg IV or PO twice daily | N/A | 14–21 |
| Children | Streptomycin | 15 mg/kg IM twice daily | 2 g per day | Minimum 10 |
| | Gentamicin* | 2.5 mg/kg IM or IV 3 times daily | Monitor serum drug levels and consult a pediatric infectious disease specialist | Minimum 10 |
| | Ciprofloxacin* | 15 mg/kg IV or PO twice daily | 1 g per day | 10 |

*Not a U.S. FDA-approved use, but has been used successfully to treat patients with tularemia.

- NOTE:** Gentamicin or streptomycin is preferred for treatment of severe tularemia. Doses of both streptomycin and gentamicin should be adjusted for renal insufficiency.
- NOTE:** Chloramphenicol may be added to streptomycin to treat meningitis.

REFERENCES

Centers for Disease Control and Prevention 2009. Tularemia—Missouri, 2000–2007. *MMWR* 58:744–748.

Dennis D, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. *JAMA* 2001. 285(21): 2763–2773.

Feldman KA, Ensore RE, Lathrop SL, et al. An outbreak of primary pneumonic tularemia on Martha’s Vineyard. *NEJM* 2001; 345: 1601–1606.

Johansson A, Berglund L, Sjöstedt A, Tärnvik. A ciprofloxacin for treatment of tularemia. *Clin Infect Dis* 2001;33:267–8.

Penn RL. *Francisella tularensis* (Tularemia). In: Mandell GL, Bennett JE, Dolin R, editors. *Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases*. 6th ed. Philadelphia, PA: Churchill Livingstone; 2005. p. 2674–2685.

Tarnvik A. WHO Guidelines on tularaemia. Vol. WHO/CDS/EPR/2007.7. Geneva: World Health Organization, 2007 http://whqlibdoc.who.int/publications/2007/9789241547376_eng.pdf

Other Tickborne Diseases

Colorado Tick Fever (CTF)

WHERE FOUND The geographic range of Colorado tick fever virus includes the western United States and southwestern Canada at elevations 4,000 to 10,000 feet. Cases occur primarily in Colorado, Utah, Montana, and Wyoming. Although rare, the virus can also be transmitted from person-to-person via blood transfusion.

INCUBATION PERIOD: 1–14 days

SIGNS AND SYMPTOMS

- Fever, chills, headache, myalgias, and lethargy
- ~50% of patients have a biphasic illness with symptoms remitting after 2 to 4 days, but then recurring 1 to 3 days later
- Conjunctival injection, pharyngeal erythema and lymphadenopathy may be present
- Maculopapular or petechial rash in <20% of patients
- Prolonged convalescence characterized by weakness and fatigue is common in adults

- Life-threatening complications and death are rare and usually associated with disseminated intravascular coagulation or meningoencephalitis in children

GENERAL LABORATORY FINDINGS

- Leukopenia
- Moderate thrombocytopenia

LABORATORY DIAGNOSIS

- Culture and RT-PCR during first 2 weeks of illness

Agent: Colorado tick fever virus

- Serologic assays (e.g., IgM-capture EIA, indirect fluorescent antibody, and plaque-reduction neutralization) on convalescent samples. IgM antibodies usually do not appear until 14–21 days after illness onset.

TREATMENT

No specific antiviral treatment is available. Patients with suspected CTF should receive supportive care as appropriate. Patients with confirmed CTF should defer blood and bone marrow donation for at least 6 months after recovery.

REFERENCES

Brackney MM, Marfin AA, Staples JE, et al. Epidemiology of Colorado tick fever in Montana, Utah, and Wyoming, 1995–2003. *Vector Borne Zoonotic Dis* 2010;10:381–385.

Centers for Disease Control and Prevention. West Nile Virus Disease and Other Arboviral Diseases—United States, 2011. *MMWR* 2012; 61(27):510–514.

Fischer M, Tsai TF. Coltiviruses (Colorado Tick Fever). In: Principles and Practice of Pediatric Infectious Diseases, 3rd edition. Eds: Long SS, Pickering LK, Prober CG. Elsevier 2008:1076–1078.

Goodpasture HC, Poland JD, Francy DB, Bowen GS, Horn KA. Colorado tick fever: clinical, epidemiologic, and laboratory aspects of 228 cases in Colorado in 1973–1974. *Ann Intern Med* 1978;88:303–310.

Lambert AJ, Kosoy O, Velez JO, Russell BJ, Lanciotti RS. Detection of Colorado Tick Fever viral RNA in acute human serum samples by a quantitative real-time RT-PCR assay. *J Virol Methods* 2007;140:43–48.

Romero JR, Simonsen KA. Powassan encephalitis and Colorado tick fever. *Infect Dis Clin North Am* 2008;22:545–559.

Spruance SL, Bailey A. Colorado Tick Fever. A review of 115 laboratory confirmed cases. *Arch Intern Med* 1973;131:288–293.

34

Tickborne Relapsing Fever (TBRF)

Agent: *Borrelia hermsii* and other spp.

WHERE FOUND In the U.S., TBRF occurs most commonly in 14 western states: Arizona, California, Colorado, Idaho, Kansas, Montana, Nevada, New Mexico, Oklahoma, Oregon, Texas, Utah, Washington, and Wyoming. Most cases occur in the summer when people vacation and sleep in rodent-infested cabins. However, TBRF can also occur in the winter months when fires started to warm a cabin activate ticks resting in the walls and woodwork.

INCUBATION PERIOD: ~7 days, followed by recurring febrile episodes that last ~3 days and are separated by afebrile periods of ~7 days

SIGNS AND SYMPTOMS

- Headache
- Myalgia
- Chills
- Nausea, vomiting
- Arthralgia

COMMON FINDINGS ON ROUTINE LABORATORY TESTS

- Normal to increased white blood cell count with a left shift
- Mildly increased serum bilirubin
- Mild to moderate thrombocytopenia

- Elevated erythrocyte sedimentation rate
- Slightly prolonged prothrombin time (PT) and partial thromboplastin time (PTT)

LABORATORY DIAGNOSIS

- Observation of *Borrelia* spirochetes in smears of peripheral blood, bone marrow, or CSF
- Organisms are best detected in blood obtained while a person is febrile
- Serologic testing for TBRF is not standardized and results may vary by laboratory

TREATMENT

- Tetracycline 500 mg every 6 hours for 10 days is the preferred oral regimen for adults. If tetracyclines are contraindicated, an effective alternative is erythromycin 500 mg (or 12.5 mg/kg) every 6 hours for 10 days.
- For CNS involvement, ceftriaxone 2 g per day for 10–14 days is preferred.
- When initiating antibiotic therapy, all patients should be observed during the first 4 hours of treatment for a Jarisch-Herxheimer reaction.
- Acute respiratory distress syndrome requiring intubation has occurred in several patients undergoing TBRF treatment.

REFERENCES

Centers for Disease Control and Prevention. Acute respiratory distress syndrome in persons with tickborne relapsing fever—Three states, 2004–2005. *MMWR* 2007; 56(41):1073–1076.

Dworkin MS, Schwan TG, et al. Tick-borne relapsing fever. *Infect Dis Clin North Am* 2008 Sep;22(3):449–8.

Hayes EB and Dennis DT. Relapsing fever. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2004:991–995.

35

Other Tickborne Diseases

Powassan Disease

Agent: Powassan virus

WHERE FOUND Powassan virus infections have been recognized in the United States, Canada and Russia. In the United States, cases have been reported primarily from northeastern states and the Great Lakes region.

INCUBATION PERIOD: 1 to 4 weeks

SIGNS AND SYMPTOMS

- Fever, headache, vomiting, and generalized weakness
- Usually progresses to meningo-encephalitis. May include meningeal signs, altered mental status, seizures, aphasia, paresis, movement disorders, or cranial nerve palsies

GENERAL LABORATORY FINDINGS

- CSF findings include lymphocytic pleocytosis (neutrophils can predominate early), normal or mildly elevated protein, and normal glucose

LABORATORY DIAGNOSIS

- No commercially-available tests; testing available at CDC and selected state health departments.
- Measurement of virus-specific IgM antibodies in serum or cerebrospinal fluid (CSF). Cross-reaction with other flaviviruses (e.g., West Nile, dengue, or St. Louis viruses) can occur; plaque reduction neutralization tests should be performed to confirm the diagnosis.
- RT-PCR may detect viral RNA in acute CSF specimens or tissues but the sensitivity is unknown and this method

should not be used to rule out the diagnosis.

TREATMENT

- No specific antiviral treatment for Powassan disease is available. Patients with suspected Powassan disease should receive supportive care as appropriate.

REFERENCES

Centers for Disease Control and Prevention. West Nile virus disease and other arboviral diseases—United States, 2011. *MMWR* 2012; 61(27):510–514.

Centers for Disease Control and Prevention. Outbreak of Powassan encephalitis—Maine and Vermont, 1999–2001. *MMWR* 2001; 50(35):761–764.

Ebel GD. Update on Powassan virus: emergence of a North American tick-borne flavivirus. *Annu Rev Entomol* 2010;55:95–110.

Gholam BI, Puksa S, Provias JP. Powassan encephalitis: a case report with neuropathology and literature review. *CMAJ* 1999;161(11):1419–1422.

Hinten SR, Beckett GA, Gensheimer KF, et al. Increased recognition of Powassan encephalitis in the United States, 1999–2005. *Vector Borne Zoonotic Dis* 2008;8(6):733–740.

Romero JR, Simonsen KA. Powassan encephalitis and Colorado tick fever. *Infect Dis Clin North Am* 2008;22(3):545–559.

Tickborne Diseases Abroad

Activities that increase risk for tick exposure worldwide include (but are not limited to): outdoor recreation such as camping, hiking, fishing, or bicycling; military training; outdoor occupations such as forestry; and collecting mushrooms, berries, or flowers in forested or agricultural areas.

| DISEASE & ETIOLOGIC AGENT(S) | GEOGRAPHIC LOCATION AND ADDITIONAL RISK FACTORS |
|--|---|
| Lyme Disease <i>Borrelia afzelii</i> , <i>Borrelia garinii</i> , <i>B. burgdorferi sensu stricto</i> | Eastern and central Europe, northern Asia |
| Tick-Borne Encephalitis Tick-borne encephalitis virus | Temperate regions of Europe and northern Asia. May also be acquired by ingestion of unpasteurized dairy products from infected goats, sheep, or cows. |
| Spotted Fever Group Rickettsioses (includes tick typhuses) <i>R. akari</i> , <i>R. parkeri</i> , <i>R. africae</i> , <i>R. japonica</i> , <i>R. felis</i> , etc. | All continents except Antarctica. <i>R. africae</i> infection has been reported as a cause of fever in travelers returning from South Africa. |
| Crimean-Congo Hemorrhagic Fever CCHF virus | Asia, Africa, and Europe. May also be acquired by contact with infected blood or saliva or inhalation of infected aerosols. |
| Omsk Hemorrhagic Fever Omsk hemorrhagic fever virus | Southwestern Russia. May also be acquired by direct contact with infected muskrats. |
| Kyasanur Forest Disease Kyasanur forest disease virus | Southern India, Saudi Arabia (aka Alkhurma disease in Saudi Arabia). Typically associated with exposure while harvesting forest products. |

NOTE: *Anaplasmosis, babesiosis, ehrlichiosis, tularemia, TBRF, and Powassan disease can also be acquired internationally. Please see disease-specific references for more information on worldwide distribution.*

REFERENCE

Goodman JL, Dennis DT, Sonenshine DE, editors. Tick-borne diseases of humans. Washington, DC: ASM Press; 2005.

Tick Bites/Prevention

Ticks are generally found near the ground, in brushy or wooded areas. They can't jump or fly. Instead, they climb tall grasses or shrubs and wait for a potential host to brush against them. When this happens, they climb onto the host and seek a site for attachment.


PREVENTION

1. Wear repellent containing at least 20% DEET or permethrin-treated clothing. Additional repellent options are available. For more information, see <http://cfpub.epa.gov/oppref/insect/>.
2. Treat dogs and cats for ticks as recommended by a veterinarian.
3. Check for ticks daily, especially under the arms, in and around the ears, inside the belly button, behind the knees, between the legs, around the waist, and on the hairline and scalp.
4. Shower soon after being outdoors.
5. For tips on "tick-safe" landscaping, see www.cdc.gov/lyme/prev/in_the_yard.html.

TICK REMOVAL

1. Use fine-tipped tweezers to grasp the tick as close to the skin's surface as possible. You may use specialized tick removal tools, if you already have them. The key is to remove the tick as soon as possible. Avoid folklore remedies such as using nail polish, petroleum jelly, or heat to make the tick detach from the skin.
2. Pull upward with steady, even pressure. Don't twist or jerk the tick; this can cause the mouth-parts to break off and remain in the skin. If this happens, remove the mouth-parts with clean tweezers. If you are unable to remove the mouth parts easily, leave them alone and let the skin heal.
3. After removing the tick, thoroughly clean the bite area and your hands with rubbing alcohol, an iodine scrub, or soap and water.

Embedded tick



38

TICK BITE PROPHYLAXIS

The Infectious Disease Society of America (IDSA) does not generally recommend antimicrobial prophylaxis for prevention of **Lyme disease** after a recognized tick bite. However, in areas that are highly endemic for Lyme disease, a single dose of doxycycline may be offered to adult patients (200 mg) who are not pregnant and to children older than 8 years of age (4 mg/kg up to a maximum dose of 200 mg) when **all** of the following circumstances exist:


- a. Doxycycline is not contraindicated.
- b. The attached tick can be identified as an adult or nymphal *I. scapularis* tick.
- c. The estimated time of attachment is ≥ 36 h based on the degree of engorgement of the tick with blood or likely time of exposure to the tick.
- d. Prophylaxis can be started within 72 h of tick removal.
- e. Lyme disease is common in the county or state where the patient lives or has recently traveled, (i.e., CT, DE, MA, MD, ME, MN, NH, NJ, NY, PA, VA, VT, WI).

Antibiotic treatment following a tick bite is not recommended as a means to prevent **anaplasmosis**, **babesiosis**, **ehrlichiosis**, or **Rocky Mountain spotted fever**. There is no evidence this practice is effective, and it may simply delay onset of disease. Instead, persons who experience a tick bite should be alert for symptoms suggestive of tickborne illness and consult a physician if fever, rash, or other symptoms of concern develop.


Tularemia prophylaxis is recommended only in cases of laboratory exposure to infectious materials:

- Doxycycline (100 mg orally BID X 14 days) is generally recommended for prophylaxis in adults.
- Ciprofloxacin (500 mg orally BID) is not FDA-approved for prophylaxis of tularemia but has demonstrated efficacy in various studies, and may be an alternative for patients unable to take doxycycline.

39



For more information please contact:
Centers for Disease Control and Prevention
Division of Vector-Borne Diseases
3156 Rampart Road, Fort Collins, CO 80521
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-63548
Contact: www.cdc.gov/cdc-info/
Web: www.cdc.gov/ticks



Based on "Tickborne Diseases in Massachusetts: A Physician's Reference Manual", produced by collaboration between MDPH, Nancy Shadick, MD, MPH, and Nancy Maher, MPH of the RBB Arthritis and Musculoskeletal Diseases Clinical Research Center at Brigham and Women's Hospital and Dennis Hoak, MD, of Martha's Vineyard Hospital.